Arecor Therapeutics PLC Director/PDMR Dealings (9170U)

TIDMAREC

RNS Number : 9170U

Arecor Therapeutics PLC

04 August 2022

4 August 2022

Arecor Therapeutics plc

("Arecor" or the "Company" or the "Group")

Director/PDMR Dealings

and

Completion of the Acquisition of Tetris Pharma

Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, announces t hat further to the Placing and acquisition of Tetris Pharma, details of which were announced on 1 August 2022, pursuant to the Placing, the following Directors subscribed for an aggregate amount of GBP113,271 at the Placing Price of 300 pence per ordinary share.

Following General Admission today, the Placing and acquisition of Tetris Pharma have now completed.

The following Directors interests in Ordinary Shares are as follows:

 
 N ame                              Placing Shares       Resultant          % of the 
                                          acquired    shareholding    Enlarged Share 
                                                         following           Capital 
                                                         Admission 
 Sarah Howell ( Chief Executive 
  Officer)                                   6,666      847,072.00              2.8% 
                                   ---------------  --------------  ---------------- 
 Susan Lowther ( Chief Financial 
  Officer)                                   3,334      139,849.00              0.5% 
                                   ---------------  --------------  ---------------- 
 Andrew Richards ( Chair)                    6,666      223,834.00              0.7% 
                                   ---------------  --------------  ---------------- 
 Sam Fazeli ( Non-Executive 
  Director)                                  7,756      115,708.00              0.4% 
                                   ---------------  --------------  ---------------- 
 J eremy Morgan ( Non-Executive 
  Director)                                  6,666       27,169.00              0.1% 
                                   ---------------  --------------  ---------------- 
 Christine Soden ( Non-Executive 
  Director)                                  6,667       19,167.00              0.1% 
                                   ---------------  --------------  ---------------- 
 Total                                      37,755 
                                   ---------------  --------------  ---------------- 
 

The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.00 a.m. on 1 August 2022 unless otherwise stated.

For more information, please contact:

 
 Arecor Therapeutics plc                    www.arecor.com 
 Dr Sarah Howell, Chief Executive Officer   Tel: [phone] 
                                             Email: [e-mail] 
 
 Susan Lowther, Chief Financial Officer     Tel: [phone] 
                                             Email: [e-mail] 
 
 Mo Noonan, Communications                  Tel: [phone] 
                                             Email: [e-mail] 
 
 Panmure Gordon (UK) Limited (NOMAD 
  and Broker) 
 Freddy Crossley, Emma Earl (Corporate      Tel: [phone] 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela         Tel: [phone] 
  Gray                                       Email: [e-mail] 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                                 a) Sarah Howell 
                                             b) Susan Lowther 
                                             c) Andrew Richards 
                                             d) Sam Fazeli 
                                             e) Jeremy Morgan 
                                             f) Christine Soden 
      ------------------------------  ------------------------------------------- 
       Reason for the notification 
  2 
      --------------------------------------------------------------------------- 
 a)    Position/status                            a) Chief Executive Officer 
                                                   b) Chief Financial Officer 
                                                   c) Chair 
                                                   d) Non-executive Director 
                                                   e) Non-executive Director 
                                                   f) Non-executive Director 
      ------------------------------  ------------------------------------------- 
 b)    Initial notification            Initial Notification 
        /Amendment 
      ------------------------------  ------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                            Arecor Therapeutics plc 
      ------------------------------  ------------------------------------------- 
 b)    LEI                             98450093D12I3A8DDD58 
      ------------------------------  ------------------------------------------- 
       Details of the transaction(s): section to be repeated 
  4     for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description of the              Ordinary Shares of 1p each 
        financial instrument, 
        type of instrument 
 
       Identification code             ISIN: GB00BMWLM973 
 
 b)    Nature of the transaction       Purchase of Ordinary Shares 
      ------------------------------  ------------------------------------------- 
 c)    Price(s) and volume(s) 
                                      ----------------------  ----------------- 
                                       Price(s)                Volume(s) 
                                      ----------------------  ----------------- 
                                            a) 300 pence            a) 6,666 
                                             b) 300 pence            b) 3,334 
                                             c) 300 pence            c) 6,666 
                                             d) 300 pence            d) 7,756 
                                             e) 300 pence            e) 6,666 
                                             f) 300 pence            f) 6,667 
                                      ----------------------  ----------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                  37,755 
 
  - Price                              300 pence 
 
 e)    Date of the transaction         4 August 2022 
      ------------------------------  ------------------------------------------- 
 f)    Place of the transaction        XLON 
      ------------------------------  ------------------------------------------- 
 

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM) , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat (TM) platform is supported by an extensive patent portfolio .

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBKQBPOBKKPFK

(END) Dow Jones Newswires

August 04, 2022 03:55 ET (07:55 GMT)